European Myeloma Network B.V.

Clinical research centers on newly diagnosed multiple myeloma, relapsed or refractory multiple myeloma, and high-risk smoldering multiple myeloma, with interest in both transplant-eligible and transplant-ineligible populations. Studies also address extramedullary disease and younger patients eligible for autologous stem cell transplantation.

• Induction therapy
• Consolidation treatment
• Maintenance therapy
• Transplant-related treatment strategies

Research activity includes combinations built around daratumumab, isatuximab, teclistamab, talquetamab, elranatamab, and ciltacabtagene autoleucel.